NCT00595686

Brief Summary

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2008

Typical duration for phase_1

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

January 7, 2008

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 16, 2008

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

May 17, 2012

Status Verified

May 1, 2012

Enrollment Period

2.3 years

First QC Date

January 7, 2008

Last Update Submit

May 15, 2012

Conditions

Hematologic Neoplasms

Keywords

Hematologic Malignancies Hsp90 Hematologic Malignancy

Outcome Measures

Primary Outcomes (1)

  • adverse events and other safety assessments

    continuous

Secondary Outcomes (1)

  • disease response specific to the hematological malignancy

    after every 2 cycles

Study Arms (1)

Single Arm

EXPERIMENTAL
Drug: SNX-5422

Interventions

SNX-5422DRUG

dose escalated; tablets every other day; undetermined duration until disease progression

Single Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 years old
  • Karnofsky performance status \> 60
  • confirmed hematological malignancy
  • refractory to available therapy or for which no therapy is available
  • adequate hepatic, renal and hematological function

You may not qualify if:

  • CNS malignancy
  • at risk for prolonged QT interval
  • significant GI/liver disease
  • other serious concurrent illness or medical condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Pfizer Investigational Site

Augusta, Georgia, 30912, United States

Location

Pfizer Investigational Site

Chapel Hill, North Carolina, 27599, United States

Location

Pfizer Investigational Site

Pittsburgh, Pennsylvania, 15232, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37232, United States

Location

Related Links

MeSH Terms

Conditions

Hematologic Neoplasms

Interventions

SNX-5422

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 7, 2008

First Posted

January 16, 2008

Study Start

January 1, 2008

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

May 17, 2012

Record last verified: 2012-05

Locations

US(4)